Zhang Zhijuan, deputy director of Policy Research Center of PhIRDA chaired the first stage.

Li Linkang, vice chairman and expert Committee on Diagnosis, Treatment and Support of Rare Diseases of the National Health Commission made a welcome remark.

Han Xiaohong, professor and director of Clinical Pharmacology Research Center, Peking Union Medical College Hospital shared Trends in Clinical Trials of Rare Diseases in China.

Chen Jia, director of Gene Editing Center, ShanghaiTech University addressed a keynote speech entitled Development and Application of New Gene Editing Tools.

Zhao Yuan, Chief Technology Officer of Jiangsu Hillgene, addressed a keynote speech entitled The Impact of EU/US Regulatory Framework on CGT Development.

Val Su, head of New Product Development Takeda China, addressed a keynote speech entitled New Ecology of Transformation on Rare Diseases Drug R&D.

Rebecca Zhang, senior vice president, Pharmaceutical Affairs, Canbridge Pharma, addressed a keynote speech entitled China Rare Disease New Drug Development Challenge and Thinking.

Liu Junshuai, member of Specialty Committee on Diagnosis, Treatment and Protection of Rare Diseases, was moderator of the panel discussion. Chen Jia, Zhang Dan, co-Founder and co-Chairman of Jiangsu Hillgene, Eileen Gu, associate director, Takeda China, and Rebecca Zhang, participated in the panel.